Receiver operator characteristic (ROC) curve of mean value DAS28(ESR) in predicting the development of type 2 diabetes (T2D).

<p>Receiver operator characteristic (ROC) curve of mean value DAS28(ESR) in predicting the development of type 2 diabetes (T2D).</p

Study design.

<p>* In the pre-recruitment screening phase, patients were excluded if presented: 1) past diagnosis of T2D previously performed by a physician <i>or</i> 2) current or past treatment with antidiabetic medications (including oral antidiabetic drugs and insulin); 3) fasting plasma glucose (FPG) ≥ 126 mg/dL in at least two separate occasions. ** In the recruitment screening phase patients were excluded if fasting plasma glucose (FPG) ≥ 126 mg/dL.</p

Logistic regression analysis for prediction of new-onset impaired fasting glucose.

<p>Logistic regression analysis for prediction of new-onset impaired fasting glucose.</p

Logistic regression analysis for prediction of new-onset type 2 diabetes.

<p>Logistic regression analysis for prediction of new-onset type 2 diabetes.</p

Demographic and clinical characteristics of the study cohort.

<p>Demographic and clinical characteristics of the study cohort.</p

Receiver operator characteristic (ROC) curve of mean value DAS28(ESR) in predicting the development of type 2 diabetes (T2D).

<p>Receiver operator characteristic (ROC) curve of mean value DAS28(ESR) in predicting the development of type 2 diabetes (T2D).</p

Predictive factors of new CVEs onset.

<p>Predictive factors of new CVEs onset.</p

Baseline clinical characteristics.

<p>Baseline clinical characteristics.</p

Traditional CV risk factors, CVEs and subclinical atherosclerosis, comparison between time 0 and 12 month.

<p>This Figure shows: A), B) and C) the increased percentages of patients affected by SAH, MS and T2D (p<0.00001 for each comparison), after 12 months of follow up. D) and E) After 12 months, we observed an increased percentage of patients experienced new CVEs and developed subclinical atherosclerosis, respectively (p<0.00001 for each comparison).</p

Effectiveness and disease activity evaluation in the enrolled patients.

<p>This Figure shows: A) and B) the progressive reduction of both DAS28 and SDAI values; C) the disease activity at the first observation and after 12 months of follow up, respectively; E) the EULAR response criteria after 12 months of follow up.</p